Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).

@article{Bahl2015FinalQO,
  title={Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).},
  author={A. K. Bahl and Susan Masson and Zafar Iqbal Malik and Alison J. Birtle and Santhanam Sundar and Robert M. Jones and Nicholas D James and Malcolm David Mason and Satish Kumar and David Martin Bottomley and Anna Lydon and Simon Chowdhury and James Pinson Wylie and Johann S de Bono},
  journal={BJU international},
  year={2015},
  volume={116 6},
  pages={880-7}
}
OBJECTIVE To compile the safety profile and quality of life (QoL) data for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel in the UK Early Access Programme (UK EAP). PATIENTS AND METHODS A total of 112 patients participated at 12 UK cancer centres. All had mCRPC with disease progression during or after docetaxel. Patients received cabazitaxel 25 mg/m(2) every 3 weeks with prednisolone 10 mg daily for up to 10 cycles. Safety assessments were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
10 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…